Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T14:52:31.679Z.
Calculation as of: 2026-10-06T14:52:31.679Z.
Quote observation: 2026-10-06T14:49:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 521b0ab3da901f2a49dafbbedcb3688a082548b97bbb2cd5efdb729e6989e7c5
PEG RATIO
N/A
TuHURA Biosciences, Inc.
Market Cap
$119.72M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| TuHURA Biosciences, Inc. (HURA) | $119.72M | N/A |
| enGene Holdings Inc. (ENGN)vs › | $121.25M | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $117.05M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $116.95M | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $116.54M | N/A |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $122.96M | N/A |
| Cibus, Inc. (CBUS)vs › | $122.89M | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $113.83M | N/A |
| MaxCyte, Inc. (MXCT)vs › | $114.62M | N/A |
| Entera Bio Ltd. (ENTX)vs › | $126.43M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
